Bubs share price sinks 11% on shocking China update

The previous management team of Bubs made some very bad business decisions.

| More on:
Close up of a sad young woman reading about declining share price on her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bubs Australia Ltd (ASX: BUB) share price is ending the week deep in the red.

In morning trade, the embattled infant formula company’s shares are down 11% to 16 cents.

Why is the Bubs share price sinking?

Investors have been hitting the sell button today after the company revealed just how bad things got for the business in China under the leadership of its previous CEO and Chair.

According to the release, full-year revenue in China is expected to be at the low end of the previous forecast range of between $13.5 million and $13.8 million. This will be a whopping ~75% reduction on FY 2022’s revenue of $53.6 million.

Bubs’ new management team blamed this on exclusive China distribution arrangements with entities affiliated with AZ Global and Willis Trading, which are below expectations and continue to disappoint.

It is unclear whether FY 2022’s China revenue was boosted by the same channel stuffing activities that contributed to the recent downfall of BWX. However, Bubs revealed that it understands there is more than 5 years of Bubs Supreme finished goods inventory held in multiple warehouses, based on the current rate of sale.

In addition, the company has stated that AZ Global and Willis Trading owe $5.65 million for finished goods that were delivered. Bubs also now holds significant amounts of bulk raw material that was purchased to meet its supply obligations under the agreement with AZ Global.

Unsurprisingly, given the state of its inventory position, the company expects to make a significant non-cash impairment of inventory with its FY 2023 results. At present, it estimates that this will be in the region of $20 million to $25 million.

SAMR plans scrapped

Bubs has decided to scrap its joint venture plans with Zhitong Health Technology and has withdrawn its SAMR application for direct access to China’s infant formula market.

Instead, the company’s new management team will now revisit its own resubmission and registration application under SAMR in respect of three slots for which nomination rights are held by the Australian Deloraine facility.

Commenting on the mess that former leaders Kristy Carr and Dennis Lin left behind, acting CEO Richard Paine said:

It is clear that the exclusive distribution agreement with AZ Global has not delivered for shareholders. Bubs will take a more strategic approach to its distribution in China going forward. Our brand is well respected in this critical market, and we need to progress with a multi-channel strategy supported by professional and experienced trade partners on the ground who can deliver us real time, valuable market insights. Bubs has a great opportunity to grow our brand presence in China, alongside the US and other international markets. We look forward to providing a broader update on our strategic review shortly.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

A woman screams and holds her hands up in frustration.
Earnings Results

Baby Bunting share price sinks 10% as profits crash

Baby Bunting has reported a huge decline in its profits today.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Consumer Staples & Discretionary Shares

Here’s what a top broker is saying about A2 Milk shares

Is this infant formula a buy? Let's see what a top broker is saying.

Read more »

A woman is excited as she reads the latest rumour on her phone.
Earnings Results

Cettire share price jumps 11% on dazzling FY23 growth

Consumer spending weakness hasn't been able to stop Cettire's rapid growth.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Consumer Staples & Discretionary Shares

‘Contrarian positioning’: 2 ASX shares to buy from an unloved sector

DNR Capital reveals the stocks that they have recently bought for cheap, going against market sentiment.

Read more »

Couple look at a bottle of wine while trying to decide what to buy.
Consumer Staples & Discretionary Shares

Should you pour Treasury Wine shares into your portfolio while they’re under $12?

Is this beaten-down stock in the $12 bargain bin?

Read more »

A woman screams and holds her hands up in frustration.
Consumer Staples & Discretionary Shares

Why is the Myer share price crashing 12% today?

Macroeconomic headwinds are starting to bite over at Myer.

Read more »

Smiling person with tattoos enjoying a glass of wine with a group of others.
Broker Notes

Could this be a very positive sign for Treasury Wine shares?

Will Chinese consumers soon be saying cheers to this company's wine again?

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
Consumer Staples & Discretionary Shares

Should I still buy Wesfarmers shares at nearly $50 a pop?

Is Wesfarmers worth a pre-earnings buy at nearly $50 a share right now?

Read more »